Skip to content
    Lightstone Ventures logo

    Lightstone Ventures

    Portola Valley, California, United StatesFounded 2012
    www.lightstonevc.comLinkedIn
    Biotech & Life SciencesHealthcare

    Lightstone Ventures is a global life-science venture capital firm founded in 2012, investing in biotech and medtech companies pioneering breakthroughs in therapeutics and medical devices. The firm builds companies from start-up through commercialization, with offices in Portola Valley, Boston, and Dublin.

    37% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 7 prior). Average disclosed round size is $68.1M (across 71 rounds with reported amounts).

    Find people at Lightstone Ventures on Goldilocks AI

    Portfolio

    48

    Fund Size

    $375M

    Top Stage

    Series A

    Last 12 Mo

    3

    Team

    MC

    Mike Carusi

    Managing Partner

    CG

    Caroline G.

    Partner

    CI

    Christina Isacson

    Partner

    CK

    Christina K. Isacson

    Partner

    HG

    Hanson Gifford

    Partner

    KN

    Kenneth Noonan

    Venture Partner

    JW

    Jingjing Wang

    Vice President

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    82 investments
    CompanyRoundAmountDate
    Crystalys Therapeutics Inc logoCrystalys Therapeutics IncSeries B$130MJul 2026
    Psithera logoPsitheraSeries A$47.5MDec 2025
    Crystalys Therapeutics Inc logoCrystalys Therapeutics IncSeries A$205MSep 2025
    Apreo Health logoApreo HealthSeries B$130MSep 2025
    ProVerum Medical logoProVerum MedicalSeries B—Aug 2025
    Allay Therapeutics logoAllay TherapeuticsSeries D$57.5MJun 2025
    Atsena Therapeutics logoAtsena TherapeuticsSeries C$150MApr 2025
    AAtsenaSeries C$150MApr 2025
    Cala Health logoCala HealthSeries C$50MMar 2025
    Reprieve Cardiovascular logoReprieve CardiovascularSeries B$61MJan 2025
    Apreo Health logoApreo HealthSeries B$130MJan 2025
    AApreoUnknown$130MJan 2025
    FIRE1 logoFIRE1Unknown$120MJan 2025
    Atsena Therapeutics logoAtsena TherapeuticsSeries C$150MJan 2025
    PPROVERUM LIMITEDSeries B$80MJan 2025
    Apreo Health logoApreo HealthSeries B$130MJan 2025
    Allay logoAllaySeries D$57.5MJan 2025
    Cala Health logoCala HealthGrowth$50MDec 2024
    Amber Therapeutics logoAmber TherapeuticsSeries A$100MJun 2024
    Cerevance logoCerevanceSeries C$51MApr 2024
    Reprieve Cardiovascular logoReprieve CardiovascularSeries A$42MJan 2024
    Amber Therapeutics logoAmber TherapeuticsSeries A$100MJan 2024
    65LAB logo65LABUnknown—Oct 2023
    Tagworks Pharmaceuticals logoTagworks PharmaceuticalsSeries A$65MJun 2023
    TTagworksSeries A$64MJun 2023
    Page 1 of 4

    Top Co-Investors

    New Enterprise Associates15 shared
    GV11 shared
    Gilde Healthcare10 shared
    Atlas Venture10 shared
    Osage University Partners9 shared
    Sofinnova Partners9 shared
    Abingworth LLP9 shared
    OrbiMed8 shared
    Cormorant Asset Management8 shared
    RA Capital Management7 shared
    SV Health Investors7 shared
    Bain Capital Life Sciences7 shared
    Endeavour Vision6 shared
    F-Prime Capital6 shared
    Intuitive Ventures6 shared
    Canaan Partners6 shared
    SR One6 shared
    Novartis Venture Fund5 shared
    Action Potential Venture Capital5 shared
    Lux Capital5 shared

    Last updated: 20 October 2026